wild-type EGFR ( 5 , 13 ) . In addition, NSCLC cells with mutant but not wild-type EGFR undergo apoptosis following gefi tinib treatment ( 5 , 13 ) .
Little is known about the effects of cetuximab on NSCLC and the effi cacy of cetuximab in EGFR mutant and wild-type NSCLC cell lines or tumors. To determine whether cetuximab, like gefitinib and erlotinib, is more effective in cells that harbor mutant EGFR than in cells with wild-type EGFR, we examined the effects of gefi tinib and cetuximab in NSCLC cell lines with and without EGFR mutations, in NIH-3T3 cells stably expressing wild-type or mutant EGFR, and in NSCLC patients whose tumors carried EGFR mutations and who were treated with both agents in sequence.
M ATERIALS AND M ETHODS Cell Culture and Reagents
Seven NSCLC cell lines -one bronchioloalveolar cancer line (H1666) and six adenocarcinoma lines (H441, A549, H3255, DFCILU-011, PC-9, and HCC827) -were used in this study. H441, H1666, and A549, which all contain wild-type EGFR, were purchased from the American Type Culture Collection (Manassas, VA). H3255 was provided by the National Cancer Institute and has been previously characterized ( 5 , 13 , 14 ) ; it is heterozygous for the L858R missense mutation in exon 21 of the EGFR gene. HCC827 was kindly provided by Dr. Adi Gazdar and has been previously characterized ( 15 ) ; it is heterozygous for the E746_A750 mutation, which is a deletion in exon 19 of the EGFR gene. PC-9 cells were kindly provided by Dr. Kazuto Nishio and have been previously characterized ( 16 , 17 ) . These cells are heterozygous for the E746_A750 mutation (K. Nishio, personal communication). DFCILU-011 cells were isolated from a male nonsmoking NSCLC patient at Dana-Farber Cancer Institute who responded clinically to gefi tinib; these cells are heterozygous for the EGFR exon 19 deletion L747_E749 ( 5 ) . DFCILU-011 cells were propagated in Dulbecco's modifi ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gemini-BioProducts, Inc., Woodland, CA), 100 U/mL penicillin, 100 U/mL streptomycin, 2 m M glutamine, and 1 m M sodium pyruvate. H1666 and H3255 cells were maintained in ACL-4 media (Life Technologies, Inc., Rockville, MD) supplemented with 5% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, and 2 m M glutamine. H441, A549, HCC827 and PC-9 cells were maintained in RPMI 1640 medium (Cellgro; Mediatech, Inc., Herndon, VA) supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, and 2 m M glutamine. All cells were grown at 37 °C in a humidifi ed atmosphere with 5% CO 2 and were in the logarithmic growth phase at the initiation of the experiments.
Gefi tinib was a gift from AstraZeneca. Stock solutions of 10 m M were prepared in dimethyl sulfoxide and stored at − 20 °C. Cetuximab (2 mg/mL; ImClone Systems Inc., Branchburg, NJ) was purchased from the pharmacy at Dana-Farber Cancer Institute and stored at 4 °C. Cetuximab was diluted in 8.48 mg/ mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic heptahydrate, and 0.42 mg/mL sodium phosphate mono basic monohydrate. The drugs were diluted in fresh DMEM con taining 0.1% FBS before each experiment, and the fi nal dimethyl sulfoxide concentration in all experiments was less than 0.1%.
Antibodies to EGFR (SC-03) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies directed against phosphorylated EGFR (pY1068), total ERK1/2, and phosphorylated ERK1/2 (pT185/pY187) were purchased from Biosource International, Inc. (Camarillo, CA). Antibodies directed against phosphorylated Akt (pS473) and total Akt were purchased from Cell Signaling Technology (Beverly, MA). The β -actin antibody was purchased from Sigma-Aldrich (St. Louis, MO).
Growth Inhibition Assay
Growth inhibition was assessed by using the MTS assay (Promega, Madison, WI). This assay, a colorimetric method for determining the number of viable cells, is based on the bioreduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) by cells to a formazan product that is soluble in tissue culture medium and can be detected spectrophotometrically. Cells diluted in 180 μ L/well of maintenance cell culture media ( see "Cell Culture and Reagents") were plated in 96-well fl at-bottom plates (Corning, Inc., Corning, NY). The number of cells for each cell line required to obtain an optical density (OD) of 1.3 -2.2 at a wavelength of 490 nm, the linear range of the assay, after 72 hours of growth was determined empirically. The number of cells per well used in these experiments were as follows: H1666, 4000 cells; H441, 6000 cells; A549, 2500 cells; H3255, 8000 cells; DFCILU-011, 10 000 cells; HCC827, 8000 cells; PC-9, 6000 cells. Twenty-four hours after plating, cell culture media were replaced with DMEM containing 0.1% FBS with and without gefi tinib or cetuximab. Gefi tinib was used at concentrations ranging from 3.3 n M to 10 m M and cetuximab at concentrations ranging from 33 ng/mL to 100 mg/mL, similar to amounts used in prior reports ( 18 -20 ) . The cells were incubated for another 72 hours. All experimental points were set up in six to 12 wells, and all experiments were repeated at least three times. The data are expressed as percentage of growth relative to that of untreated control cells. Each data point represents the mean value (percentage) and 95% confi dence interval (CI). To make it possible to compare cells treated with gefi tinib and cetuximab, the concentrations were expressed relative to the maximum achievable serum concentration (i.e., 1 m M for gefi tinib and 100 μ g/mL for cetuximab) to obtain standardized relative doses and allow for graphical comparisons of the effects of the two drugs. The data were displayed graphically using GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, CA). The curves were fi tted using a nonlinear regression model with a sigmoidal dose response.
Western Blotting
Cells were seeded on 3-cm 2 cell culture plates at a density of 0.6 × 10 6 to 0.9 × 10 6 cells/plate and allowed to grow overnight in appropriate maintenance cell culture media for each cell line ( see "Cell Culture and Reagents") containing 5% -10% FBS. The media were then replaced with DMEM containing 0.1% FBS with or without increasing concentrations of gefi tinib (10 n M -10 μ M ) or cetuximab (100 ng/mL -100 μ g/mL). The cells were incubated for another 24 hours (NSCLC cell lines) or 8 hours (NIH3T3 cells). Cells were washed with ice-cold phosphatebuffered saline (PBS) and scraped immediately after adding 30 -75 μ L of lysis buffer (see below). The protein lysates were collected in 1.5-mL microcentrifuge tubes. For evaluation of levels of phosphorylated EGFR, the lysates were immediately boiled at 100 °C for 7 minutes (this treatment quickly denatures cetuximab and was done whether or not samples were from cells treated with cetuximab). All lysates were centrifuged at 14 000 relative centrifugal force (rcf) for 10 minutes, and supernatants (protein extracts) were collected. The protein extracts were separated by electrophoresis on 7.5% polyacrylamide -sodium dodecyl sulfate (SDS) gels and transferred to nitrocellulose membranes (Schleincher and Schuell, Dassel, Germany) by electroblotting. The membranes were incubated with 5% nonfat skin milk diluted in TBS-T (10 m M Tris [pH 7.4], 150 m M NaCl, 0.05% Tween 20) for 1 hour to block nonspecifi c binding and were then incubated with appropriate primary antibodies under the conditions recommended by the manufacturers. The blots were then washed with TBS-T for 30 minutes and incubated with horseradish peroxidase -conjugated secondary antibody (Amersham Biosciences, Buckinghamshire, UK) for 1 hour. Antibody binding was detected using an enhanced chemiluminescence system (New England Nuclear Life Science Products, Inc., Boston, MA).
Previous studies have suggested that cetuximab can induce EGFR autophosphorylation in cells that are lysed with buffers that contain only mild detergent ( 18 , 19 ) . This artifi cial autophosphorylation can be eliminated by using lysis buffers that contain more than 0.1% SDS ( 18 ) . Therefore, to avoid this artifact, for studies that evaluated the effects of gefi tinib or cetuximab on EGFR phosphorylation we used lysis buffer containing 1% SDS sodium orthovanadate, aprotinin at 2 mg/mL, and leupeptin at 5 mg/mL), as used in our previous studies ( 5 , 13 ) . Gefi tinib inhibited EGFR phosphorylation at similar concentrations, regardless of whether 1% SDS or NP-40 lysis buffer was used (data not shown).
Apoptosis Analysis
We assessed levels of apoptosis induced by gefi tinib or cetuximab using fl uorescence-activated cell sorter (FACS) analysis and immunoblotting for PARP. Cells were seeded at densities of 0.7 -1.0 × 10 5 cells/plate in 10-cm 2 plates (Becton Dickinson, Franklin Lakes, NJ) for FACS analysis and 0.35 -0.5 × 10 6 cells/ plate in 3-cm 2 plates (Becton Dickinson) for analysis of PARP cleavage. Twenty-four hours after plating, cell culture media were replaced by 15 mL (FACS analysis) or 5 mL (PARP analysis) of DMEM that contained 0.1% FBS with and without gefitinib (1 μ M ) or cetuximab (10 μ g/mL), and the cells were incubated for another 72 hours. The cells were treated with trypsin, harvested, and collected by centrifuging at 14 000 rcf for 5 min. For FACS analysis, the collected cells were fi xed overnight in 1 mL 40% ethanol at 4 °C. Fixed cells were then treated with 500 μ g/mL RNase A (Sigma) and resuspended in 500 μ L of 69 μ M propidium iodide (Sigma). FACScan and Cell Quest software (Becton Dickinson) were used to analyze the proportions of subdiploid (i.e., apoptotic) cells ( 13 ) . For PARP analysis, the collected cells were washed twice with ice-cold PBS and lysed in NP-40 lysis buffer. Subsequent immunoblotting procedures were performed as described above, and PARP was detected with a PARP antibody (Cell Signaling Technology).
EGFR Mutant Constructs and Retroviral Infection
The human EGFR gene was cloned into pDNR-Dual (BD Biosciences, San Jose, CA). Two mutants were constructed using the Quick Change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. The L858R mutation was constructed using the following oligonucleotides: sense 5 ′ -CACAGATTTTGGGCGGGCCAAACTGCTGGG-3 ′ and antisense 5 ′ -CCCAGCAGTTTGGCCCGCCCAAAATCTGTG-3 ′ . The deletion mutation L747_S752del, P753S was constructed using the following oligonucleotides: sense 5 ′ -CCGTCGCTATCA AGGAATCGAAAGCCAACAAGGAAA-3 ′ and antisense 5 ′ -TT TCCTTGTTGGCTTTCGATTCCTTGATAGCGA CGG-3 ′ . Both mutations were confi rmed by DNA sequencing. As a control for transfection, we used a retroviral construct expressing green fl uorescent protein (GFP) that has been previously described ( 21 ) . All constructs (including the GFP construct) were shuttled into the retroviral vector JP1520 using the BD Creator System (BD Biosciences). NIH-3T3 cells were infected with retrovirus according to standard protocols, as described previously ( 21 , 22 ) .
Patients and EGFR Sequencing
We searched for patients with advanced NSCLC who had been treated with both gefi tinib and cetuximab and whose tumors were known to contain an EGFR mutation from the clinical practices of the Dana-Farber Cancer Institute, the Beth Israel Deaconess Medical Center, and the Indiana University Medical Center. We identifi ed four patients who were treated sequentially with both cetuximab and gefi tinib, three of whom were treated with cetuximab in a phase II clinical trial ( 23 ) . In all cases, tumor specimens had been obtained prior to any gefi tinib or cetuximab therapy. Tumor tissue was separated from normal tissue by dissection prior to DNA preparation to yield tumor cell populations that were at least 70% pure. DNA was extracted by standard techniques, and exons 18 -24 of the EGFR gene were sequenced as previously described ( 5 ) . The EGFR primers and sequencing techniques have been previously published ( 5 ) . All patients provided written informed consent for tumor DNA sequencing and were part of an IRB-approved study at the Dana-Farber Cancer Institute.
Statistical Analysis
Statistical analyses were performed using StatView version 5.01 (SAS Institute, Cary, NC). Paired Student's t test was used to determine whether the percentage of apoptosis differed between gefi tinib and cetuximab treatments. A P value of less than .05 was considered to be statistically signifi cant. All statistical tests were two-sided.
The overall differences between the dose -response curves of cetuximab and gefi tinib in each cell line were analyzed nonparametrically. Because of the different dosing units used for cetuximab ( μ g/mL) and gefi tinib ( μ M ), the original doses were expressed as a fraction of their respective maximum concentration in serum (i.e., 100 μ g/mL for cetuximab and 1 μ M for gefitinib) to obtain standardized relative doses for analysis. In particular, cetuximab doses were divided by 100 μ g/mL, whereas gefi tinib doses remained the same as the maximum serum concentration, i.e., 1 μ M . At each standardized relative dose, the mean OD of cells treated with each drug was estimated from replicate experiments, typically six, except that 12 replicates were used to determine the mean OD in the absence of drug. The difference between the mean ODs of cetuximab-and gefi tinibtreated cells at a given standardized relative dose was analyzed by the Jonckheere -Terpstra test to determine whether the trend has a natural ordering associated with the increasing range of standardized relative doses. Because OD and percent control are linearly related, the analysis is invariant using either outcome. Two-sided P values were computed by an exact algorithm using StatXact (Cambridge, MA).
R ESULTS

Effects of Gefi tinib and Cetuximab on Growth and Apoptosis of NSCLC Cell Lines
We used the MTS assay to examine the effects of gefi tinib and cetuximab on the growth of six NSCLC cell lines in vitro. Three cell lines (A549, H441, and H1666) have wild-type EGFR and have previously been found to be resistant (A549 and H441) or moderately sensitive (H1666) to gefi tinib in vitro ( 5 , 13 ) . The other three cell lines contain mutant EGFR (L858R in HC3255 cells, L747_E749del in DFCILU-011 cells, and E746_A750del in PC-9 cells). H3255 and PC-9 cells have previously been shown to be sensitive to gefi tinib in vitro ( 5 , 13 , 16 ) . We used a wide range of concentrations of gefi tinib (3.3 n M -10 μ M ) and cetuximab (100 ng/mL -100 μ g/mL). According to pharmacokinetic data obtained in phase I clinical studies, the mean steady-state plasma concentrations of gefi tinib at the FDA-approved dosing (250 mg/day) ranges from 0.4 μ M to 1.4 μ M ( 24 ) . On the basis of these fi ndings we chose 1 μ M as the defi nition of the maximum achievable plasma concentration for gefi tinib. According to the manufacturer, at the FDA-approved dosing level of cetuximab, the mean steady-state peak and trough concentrations across various studies range from 168 to 235 μ g/mL and from 41 to 85 μ g/mL, respectively. We thus chose 100 μ g/mL as the maximum achievable serum concentration to refl ect an intermediate point of these values.
Growth was assayed 72 hours after the cells were exposed to each drug or to medium alone (control). In cell lines with wildtype EGFR (A549, H441, and H1666), the agents had similar effects on cell growth (A549: P = .38; H441: P = .77, H1666: P = .56) ( Fig. 1, A ) . In H441 and A549 cells, both gefi tinib and cetuximab showed little effect on cell growth except gefi tinib at concentrations of at least 1 μ M (i.e., 0 on x axis in Fig. 1 ), which is equivalent to the maximum serum concentration at the FDAapproved dosing. Thus, we considered H441 and A549 cells to be resistant to both gefi tinib and cetuximab. On the other hand, H1666 cells were more sensitive to both gefi tinib and cetuximab than H441 or A549 cells. However, there was no statistically signifi cant difference between the effects of gefi tinib and cetuximab in H1666 cells ( P = .56). Although IC 50 s (i.e., the drug concentrations required for 50% inhibition of growth) for H1666 were 4 μ M for gefi tinib and 33 μ g/mL for cetuximab, we observed substantial growth inhibition at much lower concentrations, and a plateau was reached ( Fig. 1, A ) .
By contrast to the cell lines with wild-type EGFR, each of which displayed similar sensitivity to gefi tinib and cetuximab, the cell lines with EGFR mutations were effectively growth inhibited by gefi tinib but not by cetuximab. Gefi tinib caused statistically signifi cantly greater growth inhibition than cetuximab in all three cell lines (H3255: P = .003, DFCILU-011: P = .011, PC-9: P = .003). IC 50 s for gefi tinib in H3255, DFCILU-011 and PC-9 were 63 n M ,10 n M , and 20 n M ( Fig. 1, B and data not shown), respectively, and much lower than those in H1666. The IC 50 s for cetuximab were not reached in the three EGFR mutant cell lines. The IC 50 s of H3255 for gefi tinib and PC-9 are consistent with previous fi ndings ( 5 , 13 , 25 ) . We tested even higher concentration of cetuximab than the limit of 100 μ g/mL shown in Fig. 1 . Even at concentrations up to 1000 μ g/mL, which is approximately 10 times higher than the maximum serum concentration of cetuximab ( 26 ) , no additional growth inhibition of H3255 cells was observed (data not shown). We chose H441 and H1666 as representative wild type cell lines and H3255 (with the L858R mutation) and DFCILU-011 (with the L747_E749 mutation) as representative EGFR mutant cell lines for further studies.
To further examine the mechanism by which gefi tinib and cetuximab inhibit growth, we treated NSCLC cell lines with 1 μ M gefi tinib, 10 μ g/mL cetuximab, or neither drug and determined the percentage of apoptotic cells by propidium iodide staining. We used these particular concentrations of each drug because they can be achieved in patient serum, because they have been used in earlier studies by us and others, and because we did not observe any additional growth inhibition for cetuximab at higher concentrations in any of the cell lines examined ( Fig. 1 )  ( 13 , 26 -29 ) . In H441 cells, neither drug had an effect on apoptosis compared with untreated control cells ( Fig. 2, A ; .8], respectively; control versus gefitinib, P = .002; control versus cetuximab, P <.001; gefi tinib versus cetuximab, P = .196), consistent with their similar degrees of growth inhibition ( Fig. 1, A ) .
In contrast to their similar effects on cells with wild-type EGFR, gefi tinib and cetuximab had statistically signifi cantly different effects on apoptosis in EGFR mutant cell lines. For H3255 cells, treatment with gefi tinib led to substantially higher levels of apoptosis than treatment with cetuximab, although cetuximab also increased apoptosis relative to control treatment ( Fig. 2, A ; mean fold increase in apoptosis by 1 μ M of gefi tinib and 10 μ g/mL of cetuximab relative to control = 8.3 [95% CI = 4.8 to 11.8] and 2.1 [95% CI = 2.0 to 2.2], respectively; control versus gefi tinib, P = .014; control versus cetuximab, P = .002; gefi tinib versus cetuximab, P = .025). For DFCILU-011 cells, treatment with gefi tinib also resulted in a statistically significant increase in apoptosis relative to cetuximab treatment, but cetuximab did not increase apoptosis relative to control treatment ( Fig. 2, A ; mean fold increase in apoptosis by 1 μ M of gefi tinib and 10 μ g/mL of cetuximab relative to control was 5.7 (95% CI = 5.1 to 6.3) and 0.9 [95% CI = 0.3 to 1.5], respectively; control versus gefi tinib, P <.001; gefi tinib versus cetuximab, P <.001). Again, these fi ndings are consistent with the differential effects of these drugs on growth of H3255 and DFCILU-011 cells ( Fig. 1, A ) .
We also assessed apoptosis by analyzing PARP cleavage, which is an indicator of caspase-mediated apoptosis, by immunoblotting ( Fig. 2, B ) . Again, we treated cells with 1 μ M gefitinib, 10 μ g/mL cetuximab, or neither drug. We obtained results that were qualitatively consistent with those of the propidium iodide analyses. That is, gefi tinib treatment led to substantial increases in levels of the cleaved fragment in H3255 and DFCILU-011 cells relative to levels in cells treated with neither drug. In H1666 cells, treatment with either drug led to increases in the level of cleaved fragment relative to that in untreated cells, whereas in H441 cells there was some baseline PARP cleavage that was not altered by either treatment.
Differential Effects of Gefi tinib and Cetuximab on Cell Signaling in NSCLC Cell Lines
To explore the molecular mechanisms underlying the difference in cellular responses to treatment with gefi tinib and cetuximab, we compared the effects of gefi tinib and cetuximab on autophosphorylation of EGFR and of the downstream signaling intermediates Akt and ERK1/2. In H441 cells, which are resistant to both gefi tinib and cetuximab, treatment with high concentrations of either drug led to a decrease in EGFR phosphorylation but did not alter phosphorylation of ERK1/2 or Akt ( Fig. 3, A ) . By contrast, both gefi tinib and cetuximab inhibited phosphorylation of both EGFR and ERK1/2 in H1666 cells, consistent with the moderate effects of these drugs on growth and apoptosis. Phosphorylation of Akt was also reduced in these cells but to a lesser extent than that of ERK1/2, as seen in our earlier study ( 13 ) . Gefi tinib treatment of the EGFR mutant cell lines H3255 and DFCILU-011 led to complete inhibition of EGFR phos phorylation and concomitant inhibition of ERK1/2 and Akt phosphorylation ( Fig. 3, B ) . By contrast, cetuximab caused only partial inhibition of EGFR, ERK1/2, and Akt phosphorylation in H3255 cells and had no effect on phosphorylation of these signaling molecules in DFCILU-011 cells ( Fig. 3, B ) . 
Effects of Gefi tinib and Cetuximab on Wild-type and Mutant EGFR Receptors
To more directly compare the inhibitor sensitivity conferred by wild-type and mutant EGFR, we stably transfected NIH-3T3 cells with different EGFR sequences. This approach eliminates differences in cellular context that could infl uence drug sensitivity. We chose NIH-3T3 cells because they have low levels of endogenous EGFR. We used wild-type EGFR and two different EGFR mutations, L858R and L747_S752del, P753S; the latter was chosen because it has been observed in patients responding to gefi tinib and was used in previous studies ( 6 , 7 ) . For controls, we transfected cells with a vector that contains the gene for green fl uorescent protein (GFP). We treated the transfected NIH-3T3 cells with a range of concentrations of gefi tinib and cetuximab. Both drugs decreased wild-type EGFR autophosphorylation only modestly and only at high concentrations (10 μ M and 100 μ g/mL, respectively) ( Fig. 4 ) . By contrast, much lower concentrations of gefi tinib (0.1 μ M and above) completely inhibited phosphorylation of both EGFR mutants. Cetuximab had no substantial effects on phosphorylation of either mutant.
An EGFR Mutant NSCLC Cell Line Growth Inhibited by Both Gefi tinib and Cetuximab
While this article was in review, Amann et al. ( 15 ) published a study demonstrating that both gefi tinib and cetuximab effectively inhibit the growth of the NSCLC cell line HCC827, which contains the E746_A750del mutation of EGFR. We thus examined the effects of both gefi tinib and cetuximab on the growth of HCC827 cells under our study conditions. Both drugs inhibited the growth of HCC827 cells, with IC 50 s of 6.6 n M and 277 ng/mL, respectively ( Fig. 5, A ) . Although both agents caused substantial growth inhibition in this cell line, gefi tinib was still statistically signifi cantly more effective than cetuximab ( P = .0028). However, whereas gefi tinib effectively inhibited EGFR phosphorylation at concentrations of 0.1 μ M or higher, cetuximab treatment did not affect EGFR phosphorylation at any concentration tested ( Fig. 5, B ) . These fi ndings are similar to those of Amann et al. ( 15 ) and are consistent with our results on cell lines carrying other EGFR mutations. Thus, HCC827 cells behaved differ ently from the other cell lines containing mutant EGFR in that cetuximab inhibited growth of HCC827 cells. However, as . In panel A, the percentage of apoptosis is given relative to the total cell population analyzed. Each experiment was repeated three times, and mean values with 95% confi dence intervals are shown. In panel B, blots were stripped and probed for β -actin as a loading and transfer control. The experiments were repeated at least twice. Fig. 3 . Effects of gefi tinib and cetuximab on phosphorylation of EGFR, Akt, and ERK1/2 non -small-cell lung cancer cell lines. A ) EGFR wild-type cell lines H441 and H1666. B ) EGFR mutant cell lines H3255 (with the L858R mutation) and DFCILU-011 (with the L747_E749del mutation). Cells were treated with gefi tinib or cetuximab at the indicated concentrations for 24 hours. Immunoblots of cellular protein were analyzed for phosphorylated and total EGFR, ERK1/2, and AKT. Blots were stripped and reprobed for β -actin as a loading and transfer control. The experiments were repeated at least twice.
in the other EGFR mutant cell lines, cetuximab had no effect on EGFR phosphorylation in HCC827 cells.
Outcome of Patients With EGFR Mutations Treated Sequentially With Cetuximab and Gefi tinib
We identifi ed four patients with advanced NSCLC with EGFR mutations in their tumors who were treated with both gefi tinib and cetuximab for relapsed disease ( Table 1 ) . Three patients were treated with cetuximab fi rst and achieved stable disease as their best response. On disease progression, these three patients were switched to gefi tinib and subsequently achieved a partial response. A fourth patient was initially treated with gefi tinib and achieved a partial response that lasted 24 months. On disease progression, he was treated with single-agent cetuximab, but his disease progressed after 8 weeks of treatment and the treatment was discontinued. Thus, the results with these patients are consistent with the observation made in NSCLC cell lines, that mutant EGFRs are more sensitive to gefi tinib than to cetuximab.
D ISCUSSION
EGFR is one of the most widely studied molecular targets for cancer therapy. We compared the effects of two different EGFR inhibitors -the small-molecule tyrosine kinase inhibitor gefi tinib, which is approved for use in patients with previously treated, advanced NSCLC, and the monoclonal antibody cetuximab, which is approved for treatment of previously treated metastatic colorectal cancer -in NSCLC cell lines carrying wild-type and mutant EGFR. The growth of NSCLC cell lines with the most common EGFR mutations (L858R and a deletion in exon 19) was inhibited by gefi tinib but not by cetuximab; the growth inhibition caused by gefi tinib appeared to result from increased apoptosis. Phosphorylation of mutant EGFRs and of the downstream signaling intermediates Akt and ERK1/2 in EGFR mutant cells was inhibited strongly by gefi tinib but only minimally by cetuximab. In cells containing wild-type EGFR, by contrast, the two inhibitors had largely similar effects. Treatment of H1666 cells with either drug caused modest growth inhibition, increased apoptosis, and decreased EGFR, Akt, and ERK1/2 phosphorylation. However, neither drug had an effect on A549 or H441 cells. Taken together, our fi ndings suggest that, although the in vitro effects of cetuximab and gefi tinib are similar in EGFR wild-type cell lines, they are different in EGFR mutant cell lines. Our results further demonstrate that these differences are likely due to the inability of cetuximab to inhibit the phosphorylation of mutant EGFR.
Despite frequent overexpression of EGFR in NSCLC, gefitinib and erlotinib (another small-molecule inhibitor of the EGFR tyrosine kinase) cause partial radiographic regressions in a small percentage of patients ( 2 -4 , 30 , 31 ) . Recent studies have demonstrated that somatic mutations in the EGFR tyrosine kinase Results are shown as means with 95% confi dence intervals. The concentrations are represented as the logarithm of the maximum achievable serum concentration for gefi tinib (1 μ M) and cetuximab (100 μ g/mL). The experiments were repeated twice. B ) Effects of gefi tinib and cetuximab on EGFR phosphorylation. Cells were treated with gefi tinib or cetuximab at the indicated concentrations for 24 hours, and phospho-and total EGFR were analyzed by immunoblotting. The blot was stripped and reprobed for β -actin as a loading and transfer control. The experiments were repeated twice.
domain are found in approximately 85% of patients who develop radiographic regressions following treatment with gefi tinib or erlotinib ( 5 -7 ) . These observations suggest that gefi tinib and erlotinib are more effective against mutant EGFR than they are against wild-type EGFR. Cetuximab has a response rate of 9% in previously treated colorectal cancer patients ( 32 ) . Only a few EGFR mutations have been detected in colorectal cancer to date, and these mutations are not associated with clinical responses to cetuximab ( 33 -35 ) . According to a preliminary report of a phase II clinical trial, the response rate to single-agent cetuximab in NSCLC patients previously treated with chemotherapy is 6% ( 23 ) . However, only limited examinations of EGFR mutation status were performed on patients treated in this study.
The fi nding that H1666 cells responded differently to the EGFR inhibitors than A549 and H441 cells, even though all three cell lines contain wild-type EGFR, is interesting and remains to be explained. One possible explanation is differences in the mutation status of K-ras. Both A549 and H441 cells have K-ras mutations, whereas H1666 have wild-type K-ras ( 13 ) . K-ras mutations have been associated with resistance to gefi tinib in vitro and in patients treated with either gefi tinib or erlotinib ( 36 , 37 ) , although such K-ras mutations have not previously been associated with resistance to cetuximab. A second possible explanation lies in the fact that EGFR undergoes autocrine activation in H1666 cells but not in the other cell lines ( 13 ) . Among the NSCLC cell lines examined in this study, H1666 and H441 secrete transforming growth factor α (TGF-α ), which suggests the presence of a TGF-α /EGFR autocrine loop ( 13 ) . These fi ndings raise the possibility that expression of wild-type K-ras and interruption of the autocrine pathway may account for growth inhibition in H1666 cells treated with cetuximab. In this context, it is interesting to note that two other cancer cell lines that are sensitive to cetuximab, A431 (epidermoid carcinoma) and DiFi (colon cancer), are also both wild type for K-ras and secrete TGF-α ( 38 -40 ) . Similarly, Raben et al. ( 41 ) recently found that three NSCLC cell lines (H332, H292 and Calu 3) are sensitive to cetuximab in vitro. All three sensitive cell lines have previously been reported to be wild type for K-ras ( 21 , 41 , 42 ) . Additional studies of K-ras in NSCLC and colorectal cancer patients treated with cetuximab may help to clarify whether mutational status of K-ras is a critical determinant of sensitivity to cetuximab.
Our studies of three different EGFR mutant NSCLC cell lines (H3255, PC-9, and DFCILU-011) demonstrated that cetuximab does not inhibit their growth in vitro, probably because it does not inhibit EGFR phosphorylation. In contrast to our fi ndings, Amann et al. ( 15 ) recently demonstrated that the growth of HCC827, an EGFR mutant (E746_A750 del) NSCLC cell line, was inhibited by both gefi tinib and cetuximab, and we made the same observation ( Fig. 5 ) . Nevertheless, like Amann et al., we also found that only gefi tinib was able to inhibit EGFR phosphorylation. This disconnect between inhibition of growth and lack of inhibition of EGFR phosphorylation, which we observed in the HCC827 cell line only, raises questions as to the mechanism by which cetuximab inhibits growth of this cell line in vitro.
Our fi nding that phosphorylation of mutant EGFRs (those in NSCLC cell lines as well as those in stably transfected NIH-3T3 cells) was completely inhibited by gefi tinib at concentrations as low as 100 n M , which is substantially below the mean plasma steady state concentration of gefi tinib (0.4 -1.4 μ M ) but was only minimally affected by even the maximum serum achievable concentration of cetuximab (i.e., 100 μ g/mL), indicates that cetuximab, which binds to the extracellular portion of EGFR, is unable to inhibit phosphorylation of the mutant EGFRs. By contrast, both drugs had minimal effects on EGFR phosphorylation in cells with wild-type EGFR. Although these fi ndings are similar to those of Lynch et al. ( 6 , 15 ) and Amman et al. ( 6 , 15 ) , they partly differ from those of Pao et al. ( 7 ) , who found that EGFR phosphorylation in cells transiently transfected with L858R but not with L747_S752del was inhibited by 10-fold lower concentrations of gefi tinib or erlotinib than were necessary to inhibit wild-type EGFR. The differences between our fi ndings and those of Pao et al. may refl ect differences in the cell lines (NIH-3T3 versus 293T cells) used and/or the amount of EGFR expression in the transfectants because we generated stable cell lines with retroviral infection, whereas Pao et al. assessed transiently transfected cells.
A potential limitation of our study is that the experiments were performed in vitro; therefore, we could not evaluate the antibody-dependent cellular cytotoxicity effects that have been observed with anti-EGFR monoclonal antibodies ( 43 ) . Because of these effects, responses to cetuximab in vivo and in vitro could be different. Indeed, Huang et al. ( 29 ) found that, in vitro, gefi tinib caused a greater degree of growth inhibition of the NSCLC line H226 than cetuximab, whereas cetuximab was more effective at inducing tumor regression in a xenograft model using these same cells. Another potential limitation lies in the fact that we examined only four EGFR mutant NSCLC cell lines with two different types of mutations (L858R and exon 19 deletion), and these may not be representative of all of the different EGFR mutations found in patients with NSCLC. However, L858R and exon 19 deletions are the most common EGFR mutations, and no NSCLC cell lines harboring mutations other than these have, to our knowledge, been described. Our study also examined more EGFR mutant NSCLC cell lines than any other previously published study.
To gain insight into the effects of cetuximab in EGFR mutant tumors in vivo, we examined the outcome of four NSCLC patients 
